SCHEMBL679932

SCHEMBL679932

Cc1cc(Cl)ccc1Oc1ccc(C(=O)NS(C)(=O)=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 12/20 0.51
SLC6A2 P23975 2/20 0.48
SLC6A4 P31645 2/20 0.48
SLC6A3 Q01959 2/20 0.48
SCN2B O60939 2/20 0.46
SCN1B Q07699 2/20 0.46
SCN5A Q14524 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
KCNH2 Q12809 1/20 0.46
PNLIP P16233 1/20 0.45
SCN1A P35498 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679856 0.92 SCN9A (0.56) SCN9ASLC6A2SLC6A4SLC6A3SCN2B
SCHEMBL681070 0.90 SCN9A (0.58) SCN9ASCN2BSCN1BSCN5ASMN1; SMN2
SCHEMBL16319447 0.88 SCN9A (0.53) SCN9ASCN5APNLIP
SCHEMBL680062 0.87 MMP13 (0.47) SCN9ASCN2BSCN1BMAPTSCN1A
SCHEMBL678799 0.86 SCN9A (0.56) SCN9ASLC6A2SLC6A4SLC6A3SCN5A
SCHEMBL680346 0.85 SCN9A (0.57) SCN9ASCN2BSCN1BSCN5ASCN1A
SCHEMBL678844 0.84 SCN9A (0.53) SCN9ASCN2BSCN1BSCN5ASCN1A
SCHEMBL16319859 0.83 MMP1 (0.56) SCN9ASCN2BSCN1BSCN5ANPC1
SCHEMBL679375 0.83 SCN9A (0.58) SCN9ASCN5APNLIP
SCHEMBL16319613 0.82 SCN9A (0.60) SCN9ASLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SCN9A 13/4885SLC6A2 693/4885SLC6A4 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.